Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

TARGETED THERAPIES

PARP inhibition — opportunities in pancreatic cancer

Nature Reviews Clinical Oncology volume 16, pages 595–596 (2019)Cite this article

Subjects

An urgent clinical need exists to improve the survival of patients with pancreatic cancer through biomarker-driven therapeutic strategies. Such approaches include the targeting of metastatic pancreatic cancer that harbours germline BRCA mutations with poly(ADP-ribose) polymerase inhibitors as maintenance therapy following platinum-based chemotherapy.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Miller, K. D. et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J. Clin. https://doi.org/10.3322/caac.21565 (2019).

    Article  PubMed  Google Scholar 

  2. Conroy, T. et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 364, 1817–1825 (2011).

    Article  CAS  Google Scholar 

  3. Von Hoff, D. D. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 369, 1691–1703 (2013).

    Article  Google Scholar 

  4. Cancer Genome Atlas Research Network. Integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell 32, 185–203 (2017).

    Article  Google Scholar 

  5. Pilie, P. G. et al. State-of-the-art strategies for targeting the DNA damage response in cancer. Nat. Rev. Clin. Oncol. 16, 181–104 (2018).

    Google Scholar 

  6. Golan, T. et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa1903387 (2019).

    Article  PubMed  Google Scholar 

  7. Gyawali, B. & Prasad, V. Combining drugs and extending treatment — a PFS end point is not sufficient. Nat. Rev. Clin. Oncol. 14, 521–522 (2017).

    Article  Google Scholar 

  8. Dahan, L. et al. FOLFIRINOX until progression, FOLFIRINOX with maintenance treatment, or sequential treatment with gemcitabine and FOLFIRI.3 for first-line treatment of metastatic pancreatic cancer: a randomized phase II trial (PRODIGE 35–PANOPTIMOX) [abstract]. J. Clin. Oncol. 36 (Suppl. 15), 4000 (2018).

    Article  Google Scholar 

  9. Hu, C. et al. Association between inherited germline mutations in cancer predisposition genes and risk of pancreatic cancer. JAMA 319, 2401–2409 (2018).

    Article  CAS  Google Scholar 

  10. Seeber, A. et al. Association of BRCA-mutant pancreatic cancer with high tumor mutational burden (TMB) and higher PD-L1 expression [abstract]. J. Clin. Oncol. 37 (Suppl. 15), 4133 (2019).

    Article  Google Scholar 

  11. Hastak, K. et al. Poly (ADP-ribose) polymerase inhibitor, an effective radiosensitizer in lung and pancreatic cancers. Oncotarget 8, 26344–26355 (2017).

    Article  Google Scholar 

  12. Tempero, M. A. NCCN guidelines updates: pancreatic cancer. J. Natl Compr. Canc. Netw. 17, 603–605 (2019).

    PubMed  Google Scholar 

  13. Stoffel, E. M. et al. Evaluating susceptibility to pancreatic cancer: ASCO provisional clinical opinion. J. Clin. Oncol. 37, 153–164 (2019).

    Article  Google Scholar 

Download references

Acknowledgements

The University of Texas MD Anderson Cancer Center is supported by the NIH Cancer Center Support Grant CA016672. This funding source had no input into study design and conduct; collection, management, analysis and interpretation of the data; preparation, review or approval of the manuscript; or the decision to submit the manuscript for publication.

Author information

Authors and Affiliations

  1. Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Shubham Pant & Timothy A. Yap

  2. Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Shubham Pant

  3. Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Anirban Maitra

  4. Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Anirban Maitra

  5. Khalifa Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Timothy A. Yap

  6. The Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Timothy A. Yap

Authors
  1. Shubham Pant
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anirban Maitra
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Timothy A. Yap
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Timothy A. Yap.

Ethics declarations

Competing interests

S.P. has received research support from Arqule, Bristol-Myers Squibb, Eli Lilly, Five Prime Therapeutics, GlaxoSmithKline. Mirati Therapeutics, Novartis,Onco Response, Red Hill Biopharma, Rgenix, Sanofi–Aventis, Sanofi US Services and Xencor, and has received consultancy fees or Speakers Bureau from 4D Pharma and Tyme. A.M. has received royalties from Cosmos Wisdom Biotechnology for a biomarker assay related to early detection of pancreatic cancer. T.A.Y. received research support from AstraZeneca, Bayer, Constellation, Eli Lilly, Jounce, Kyowa, Pfizer, Seattle Genetics, Tesaro and Vertex Pharmaceuticals, and has been a consultant for Aduro, Almac, AstraZeneca, Atrin, Bayer, Bristol-Myers Squibb, Calithera, Clovis, Cybrexa, EMD Serono, Ignyta, Jansen, Merck, Pfizer, Roche, Seattle Genetics and Vertex Pharmaceuticals

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pant, S., Maitra, A. & Yap, T.A. PARP inhibition — opportunities in pancreatic cancer. Nat Rev Clin Oncol 16, 595–596 (2019). https://doi.org/10.1038/s41571-019-0257-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41571-019-0257-6

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing